Nanōmix eLab® COVID-19 Rapid Antigen Panel

COVID-19 Antigen Rapid Point of Care
to detect COVID-19 (SARS-CoV-2)

elab system





The Nanōmix eLab® Covid-19 Cartridge has been submitted for Emergency use Authorization (EUA) to U.S. Food and Drug Administration (FDA).



The Nanōmix COVID-19 Rapid Antigen Test

Designed to provide qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal (anterior nares) swabs. Nasal swab samples are collected using a provided swab and sample collection tube and then transferred to the single-use, microfluidic cartridge.

The cartridge is run on the Nanōmix eLab® Analyzer which displays and provides electronic results in 15 minutes with the ability to print or send results via bluetooth. Additionally, the eLab system can publish Nanōmix eLab® COVID-19 Rapid Antigen Test results output as a QR code for privacy.



Nanomix eLab

The test is an important addition to the diagnostics currently available for patients suspected to have, or to have previously had, COVID-19. The handheld Nanōmix eLab® analyzer allows for accurate point-of-care testing. The Nanōmix eLab COVID-19 (SARS-CoV-2) Rapid Cartridge test is designed to support the many, varied settings still in need of increased testing.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures under Contract No. 75A50120C00060.







SARS-CoV-2 Infection Associated Assays and Pipeline